Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance

Tumor Biology

Volumn 39, Issue 4, 2017, Pages

  Deng, Jun ^a   Wang, Yi ^a   Lei, Jun ^a   Lei, Wan ^a   Xiong, Jian Ping ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

5 fluorouracil; drug resistance; long noncoding RNA; microRNA

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; HISTONE DEACETYLASE 4; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 125B; MICRORNA 148B; MICRORNA 192; MICRORNA 200C; MICRORNA 21; MICRORNA 215; MICRORNA 23A; MICRORNA 27; MICRORNA 27A; MICRORNA 27B; MICRORNA 365; MICRORNA 381; MICRORNA 488; MICRORNA 494; MICRORNA 497; MICRORNA 520G; MICRORNA 582 5P; MICRORNA 612; PROTEIN BCL 2; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ANTINEOPLASTIC ANTIMETABOLITE;

3' UNTRANSLATED REGION; APOPTOSIS; AUTOPHAGY; CANCER CELL LINE; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MICROARRAY ANALYSIS; MISMATCH REPAIR; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; BLOOD; PHYSIOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AUTOPHAGY; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUOROURACIL; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; RNA, UNTRANSLATED;

EID: 85018599990     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317697553     Document Type: Review

References (102)

1. Pinedo HM, Peters GF., Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653–1664.
2. Longley DB, Harkin DP, Johnston PG., 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338.
3. Patel K, Yerram SR, Azad NA. A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing. Oncotarget 2012; 3: 678–685.
4. Noguchi T, Tanimoto K, Shimokuni T. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004; 10: 7100–7107.
5. Croce CM, Calin GA., MiRNAs, cancer, and stem cell division. Cell 2005; 122: 6–7.
6. Su Z, Yang Z, Xu Y. MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget 2015; 6: 8474–8490.
7. Nandy SB, Arumugam A, Subramani R. MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the Hippo signaling pathway. Oncotarget 2015; 6: 17366–17378.
8. Xia J, Wu Z, Yu C. MiR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol 2012; 227: 470–480.
9. Kurokawa K, Tanahashi T, Iima T. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol 2012; 47: 883–895.
10. He X, Li J, Guo W. Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. Oncotarget 2015; 6: 2302–2314.
11. Hou N, Han J, Li J. MicroRNA profiling in human colon cancer cells during 5-fluorouracil-induced autophagy. PLoS ONE 2014; 9: e114779.
12. Bartel DP., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
13. Erson AE, Petty EM., MicroRNAs in development and disease. Clin Genet 2008; 74: 296–306.
14. Yang D, Sun Y, Hu L. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013; 23: 186–199.
15. Jiang L, Wang C, Lei F. MiR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway. Oncotarget 2015; 6: 8286–8299.
16. Yu X, Li Z., The role of MicroRNAs expression in laryngeal cancer. Oncotarget 2015; 6: 23297–23305.
17. Deng J, Lei W, Xiang X. Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway. Oncotarget 2016; 7: 10037–10050.
18. Mishra PJ, Humeniuk R, Mishra PJ. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 2007; 104: 13513–13518.
19. Zhang Y, Qu X, Teng Y. Cbl-b inhibits P-gp transporter function by preventing its translocation into caveolae in multiple drug-resistant gastric and breast cancers. Oncotarget 2015; 6: 6737–6748.
20. Lopes-Rodrigues V, Seca H, Sousa D. The network of P-glycoprotein and microRNAs interactions. Int J Cancer 2014; 135: 253–263.
21. Shang Y, Zhang Z, Liu Z. MiR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014; 33: 3267–3276.
22. Xia L, Zhang D, Du R. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372–379.
23. Zhang H, Tang J, Li C. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett 2015; 356: 781–790.
24. (waf1/cip1). Br J Cancer 2014; 111: 339–354.
25. Deng J, Lei W, Xiang X. MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1. Tumour Biol 2015; 36: 6823–6831.
26. Rhodes LV, Martin EC, Segar HC. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget 2015; 30(6): 16638–16652.
27. Puisieux A, Brabletz T, Caramel J., Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16: 488–494.
28. Liao H, Bai Y, Qiu S. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 2015; 6: 8914–8928.
29. Jakob C, Aust DE, Meyer W. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004; 204: 562–568.
30. Gotanda K, Hirota T, Matsumoto N. MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells. BMC Cancer 2013; 13: 369.
31. Li T, Gao F, Zhang XP., MiR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Oncol Rep 2015; 33: 607–614.
32. Boni V, Bitarte N, Cristobal I. MiR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidylate synthase regulation. Mol Cancer Ther 2010; 9: 2265–2275.
33. Hirota T, Date Y, Nishibatake Y. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 2012; 77: 16–23.
34. Offer SM, Butterfield GL, Jerde CR. MicroRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 2014; 13: 742–751.
35. Chai J, Dong W, Xie C. MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life 2015; 67: 191–201.
36. Deng J, Lei W, Fu JC. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 2014; 443: 789–795.
37. Lin C, Li X, Zhang Y. The microRNA feedback regulation of p63 in cancer progression. Oncotarget 2015; 6: 8434–8453.
38. Liao JM, Cao B, Zhou X. New insights into p53 functions through its target microRNAs. J Mol Cell Biol 2014; 6: 206–213.
39. Dong L, Deng J, Sun ZM. Interference with the β-catenin gene in gastric cancer induces changes to the miRNA expression profile. Tumour Biol 2015; 36: 6973–6983.
40. Nie J, Liu L, Zheng W. MicroRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 2012; 33: 220–225.
41. Chen B, Duan L, Yin G. MiR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother 2013; 25: 229–238.
42. Wan LY, Deng J, Xiang XJ. MiR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun 2015; 457: 125–132.
43. Song B, Wang Y, Xi Y. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28: 4065–4074.
44. Kim SA, Kim I, Yoon SK. Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells. Arch Pharm Res 2015; 38: 239–248.
45. Sacconi A, Biagioni F, Canu V. MiR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 2012; 3: e423.
46. Karaayvaz M, Zhai H, Ju J., MiR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis 2013; 4: e659.
47. Wang BD, Kline CL, Pastor DM. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer 2010; 9: 98.
48. Yin J, Tang HF, Xiang Q. MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of Bcl-2 family proteins. Pharmazie 2011; 66: 975–981.
49. Nishida N, Yamashita S, Mimori K. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012; 19: 3065–3071.
50. Yang X, Yin J, Yu J. MiRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep 2012; 27: 250–257.
51. Shang J, Yang F, Wang Y. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. J Cell Biochem 2014; 115: 772–784.
52. Yin J, Zheng G, Jia X. A Bmi1-miRNAs cross-talk modulates chemotherapy response to 5-fluorouracil in breast cancer cells. PLoS ONE 2013; 8: e73268.
53. Xu L, Beckebaum S, Iacob S. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014; 60: 590–598.
54. Li QQ, Chen ZQ, Cao XX. Involvement of NF-κβ/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 2011; 18: 16–25.
55. Amankwatia EB, Chakravarty P, Carey FA. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer 2015; 112: 1480–1490.
56. Tang J, Tao ZH, Wen D. MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling. Biochem Biophys Res Commun 2014; 447: 210–215.
57. Yu Y, Sarkar FH, Majumdar AP., Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 2013; 6: 180–186.
58. Shen WW, Zeng Z, Zhu WX. MiR-142–3p functions as a tumor suppressor by targeting CD133, ABCG2, and LGr5 in colon cancer cells. J Mol Med 2013; 91: 989–1000.
59. Valeri N, Gasparini P, Braconi C. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A 2010; 107: 21098–21103.
60. Valeri N, Gasparini P, Fabbri M. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 2010; 107: 6982–6987.
61. Jiang JX, Gao S, Pan YZ. Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol Med Rep 2014; 10: 995–1002.
62. He J, Xie G, Tong J. Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. Cell Biochem Biophys 2014; 70: 1343–1350.
63. Guo ST, Jiang CC, Wang GP. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013; 32: 1910–1920.
64. Zhao Y, Zhao L, Ischenko I. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Target Oncol 2015; 10: 535–548.
65. Zhang Y, Geng L, Talmon G. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem 2015; 290: 6215–6225.
66. Zhao G, Zhang JG, Liu Y. MiR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol Cancer Ther 2013; 12: 83–93.
67. Shi L, Wu L, Chen Z. MiR-141 activates Nrf2-dependent antioxidant pathway via down-regulating the expression of Keap1 conferring the resistance of hepatocellular carcinoma cells to 5-fluorouracil. Cell Physiol Biochem 2015; 35: 2333–2348.
68. Xiao J, Peng F, Yu C. MicroRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Int J Clin Exp Pathol 2014; 7: 7442–7450.
69. Tang H, Zhang P, Xiang Q. Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells. Pharmazie 2014; 69: 287–292.
70. Besbes S, Mirshahi M, Pocard M. New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget 2015; 6: 12862–12871.
71. Ashkenazi A., Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest 2015; 125: 487–489.
72. Siemens H, Jackstadt R, Kaller M. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 2013; 4: 1399–1415.
73. Weirauch U, Beckmann N, Thomas M. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia 2013; 15: 783–794.
74. Zhang XF, Li KK, Gao L. MiR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPβ. Oncotarget 2015; 6: 4144–4158.
75. Hanahan D, Weinberg RA., Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
76. Bedi U, Mishra VK, Wasilewski D. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget 2014; 5: 2016–2029.
77. Devaud N, Gallinger S., Chemotherapy of MMR-deficient colorectal cancer. Fam Cancer 2013; 12: 301–306.
78. Wang J, Wang H, Liu A. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget 2015; 6: 19456–19468.
79. Mitsuhashi K, Yamamoto I, Kurihara H. Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy. Oncotarget 2015; 6: 22114–22125.
80. Ferracin M, Lupini L, Salamon I. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget 2015; 6: 14545–14555.
81. Wang LJ, He CC, Sui X. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 2015; 6: 5932–5946.
82. Tomimaru Y, Eguchi H, Nagano H. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010; 103: 1617–1626.
83. Hwang JH, Voortman J, Giovannetti E. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 2010; 5: e10630.
84. Perez-Carbonell L, Sinicrope FA, Alberts SR. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer 2015; 113: 83–90.
85. Zhang PF, Sheng LL, Wang G. MiR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget 2016; 7: 35284–35292.
86. Diaz T, Tejero R, Moreno I. Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol 2014; 109: 676–683.
87. Li S, Gao J, Gu J. MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery. Med Oncol 2013; 30: 549.
88. Lin XJ, Chong Y, Guo ZW. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015; 16: 804–825.
89. Victoria Martinez B, Dhahbi JM, Nunez Lopez YO. Circulating small non-coding RNA signature in head and neck squamous cell carcinoma. Oncotarget 2015; 6: 19246–19263.
90. Tong F, Cao P, Yin Y. MicroRNAs in gastric cancer: from benchtop to bedside. Dig Dis Sci 2014; 59: 24–30.
91. Chen Q, Xia HW, Ge XJ. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev 2013; 14: 7421–7426.
92. Kjersem JB, Ikdahl T, Lingjaerde OC. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol 2014; 8: 59–67.
93. Di Gesualdo F, Capaccioli S, Lulli M. A pathophysiological view of the long non-coding RNA world. Oncotarget 2014; 5: 10976–10996.
94. Shi X, Sun M, Wu Y. Post-transcriptional regulation of long noncoding RNAs in cancer. Tumour Biol 2015; 36: 503–513.
95. Hudson WH, Ortlund EA., The structure, function and evolution of proteins that bind DNA and RNA. Nat Rev Mol Cell Biol 2014; 15: 749–760.
96. Zhang Z, Zhu Z, Watabe K. Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ 2013; 20: 1558–1568.
97. Kim T, Cui R, Jeon YJ. MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression. Oncotarget 2015; 6: 18780–18789.
98. Yang L, Lin C, Jin C. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013; 500: 598–602.
99. Xiong W, Jiang YX, Ai YQ. Microarray analysis of long non-coding RNA expression profile associated with 5-fluorouracil-based chemoradiation resistance in colorectal cancer cells. Asian Pac J Cancer Prev 2015; 16: 3395–3402.
100. Lee H, Kim C, Ku JL. A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells. Mol Cells 2014; 37: 540–546.
101. Han Y, Ye J, Wu D. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer 2014; 14: 932.
102. Redis RS, Sieuwerts AM, Look MP. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 2013; 4: 1748–1762.